检测艾滋病患者外周血HIV-1 DNA水平的竞争性PCR方法的建立

定量检测艾滋病患者体内荷毒水平对于评价治疗效果和研究发病机理至关重要 ,我们建立了一种检测 HIV- 1DNA水平的竞争性 PCR方法 ( QC- PCR)。选择 HIV- 1的高度保守区域 gag基因作为靶序列 ,以重组 PCR方法和基因克隆技术构建两种重组质粒 ,分别插入有 gag和 Δ gag片段 ,其中后者比前者内部缺失 50 bp,用作定量检测中的竞争模板。将梯度稀释的竞争模板加入到反应体系中与待测的野生型模板共同扩增 ,PCR产物经 8%聚丙烯凝胶电泳后进行密度扫描测定 ,结果表明该方法稳定可靠 ;8份艾滋病患者的 PBMC DNA标本经该方法的检测也得到较好的结果。我们认为 QC- PCR是一种较为理想的 HIV- 1DNA水平的定量方法 ,非常适合于临床标本的检测和治疗研究的应用。     

梅毒患者治疗后血清学转归的影响因素探讨

目的探讨影响梅毒治疗后血清转归的相关因素。方法回顾性研究226例HIV阴性梅毒患者的临床资料,观察驱梅治疗1年后血清痊愈或血清固定发生的情况,对影响血清固定的患者年龄、病期、性别、快速血浆反应素环状卡片试验（RPR）初始滴度、治疗用药等因素进行多因素Logistic分析。结果226例患者中,154例（68．1％）血清痊愈,72例（31．9％）发生血清固定,随着病期延长,血清固定发生率增加。多因素Logistic分析结果显示,驱梅治疗后发生血清固定的因素包括：女性患者（OR=2．517,95％CI：1．159～5．464）、初始RPR滴度≤1：16（OR=4．370,95％C1：1．311-14．562）和非苄星青霉素治疗（OR=4．959,95％CI：1．650-14．901）,而与血清学痊愈相关的临床特征包括：一期梅毒和二期梅毒患者和年轻患者（≤25岁）（均P〈0．05）。结论梅毒治疗后血清学痊愈或固定与患者病期、性别、年龄、RPR基线滴度、治疗药物有关。     

贝利木单抗靶向治疗系统性红斑狼疮的研究进展

系统性红斑狼疮是一种系统性自身免疫性疾病,确切的发病机制尚未完全清楚,B细胞的异常激活是系统性红斑狼疮发病过程中的关键环节,B细胞激活因子对于B细胞的异常激活至关重要.贝利木单抗是一种人源化单克隆抗体,可选择性识别、阻止血清中游离B淋巴细胞刺激因子.贝利木单抗对系统性红斑狼疮的疗效和安全性在随机、双盲、大规模的临床试验中得到肯定,其疗效高、不良反应少、耐受性高,是一种有发展前景的治疗系统性红斑狼疮的生物制剂.     

药物斑贴试验与药疹

药疹是指正常剂量的药物经过多种途径进入人体后引起的皮肤黏膜的损害,其病理生理学发病机制不明.药疹的临床表现多样,了解药疹的分类及发病机制对其诊断和寻找可疑致敏药物至关重要.药物斑贴试验的目的是寻找引起药疹的致敏药物,提供患者可能的致敏药物信息.近年来应用于临床的药物斑贴试验安全性较高、操作简便,为药疹的诊断提供了重要的依据.有关药物斑贴试验的相关研究较多,但结果不一.     

基质金属蛋白酶家族和皮肤黑素瘤

皮肤黑素瘤是常见的恶性肿瘤，具有高度侵袭和转移能力。降解细胞外基质是肿瘤侵袭和转移的关键，研究显示，基质金属蛋白酶家族不但介导肿瘤细胞对宿主细胞外基质的降解，还影响肿瘤新生血管生成、影响细胞黏附分子的功能、影响肿瘤细胞和非基质蛋白之间的相互作用，以及调控肿瘤细胞的凋亡等。基质金属蛋白酶和黏附分子，生长因子相互作用，调控肿瘤细胞凋亡和血管形成。     

In vitro evaluation of the intensifying photodynamic effect due to the presence of plasmonic hollow gold nanoshells loaded with methylene blue on breast and melanoma cancer cells

BackgroundHypoxia is one of the most important limiting factors in photodynamic therapy that can reduce the effectiveness of this treatment. By designing a nanocomplex of plasmonic nanoparticles and photosensitizers with similar optical properties, the rate of free oxygen radical production can be increased and the efficiency of photodynamic therapy can be improved. in this study, we tried to use the outstanding capacities of hollow gold nanoshells (HGNSs) as a plasmonic nanocarrier of methylene blue (MB) to improve the performance of photodynamic therapy.Methods and materialAfter synthesis and optimization of hollow gold nanoshells loaded with Methylene blue (HGNSs-PEG-MB), the characteristics of MB, HGNSs, HGNSs-PEG, HGNSs-PEG-MB, and their toxicity at different concentrations on the cell lines was determined. After determining of optimum concentration of nano agents, irradiation of cell was performed with non-coherent of light source with 670 nm wavelength and an intensity of 14.9 mW/cm². Twenty-four hours after irradiation, an MTT assay was used to determine cell survival percentage. To compare the results, we defined different indexes such as treatment efficiency (TE), synergism ratio (SYN), and the amount of exposure required for 50% cell death (ED50). All the tests were repeated at least four times on the DFW and MCF-7 cancer cell lines.ResultsFor combination therapies with Lumacare irradiated HGNSs-PEG-MB, the UC index was less than one for all concentrations (P < 0.05). Also, the IC50 index for this nanostructure in non-irradiated conditions and less than 9 min irradiation time was lower than other treatment groups (P < 0.05). ED50 amounts for HGNSs-PEG-MB in all concentrations were greater than the other groups. TE Index was also reported to be greater than 1 in all irradiation conditions and concentrations.ConclusionIn this study, HGNSs-PEG in the role of nanocarriers for methylene Blue was used. The results showed that irradiated HGNSs-PEG-MB by 670 nm light severely induced cell death and greatly improved the efficiency of photodynamic therapy in melanoma and breast cancer cells.     

复方紫灵胶囊致肝损伤原因分析

对案例、制剂及药材来源进行排除分析,查找复方紫灵胶囊致肝损伤的原因.推测制剂引起肝损伤的主要原因与药材补骨脂产地变化有关.为避免院内中药制剂致肝损伤的不良反应重复发生,医院必须监控药材产地.     

具有黑棘皮病表现的表皮痣2例

报告2例具有黑棘皮病表现的表皮痣.2例均为男性,16岁发病,皮损为黑棘皮病表现,但仅局限于单侧腹部和下肢,不超过人体正中线,持续存在而不累及黑棘皮病的其他好发部位.皮损分布与神经支配区域及皮纹线无明显相关性,而更符合沿Blaschko线走行的规律.组织病理学改变符合黑棘皮病.经维A酸类药物口服和外用治疗,近期疗效满意.